Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02638519
Recruitment Status : Unknown
Verified October 2017 by Thunder Bay Regional Research Institute.
Recruitment status was:  Recruiting
First Posted : December 23, 2015
Last Update Posted : August 9, 2018
Sponsor:
Collaborators:
Lakehead University
Thunder Bay Regional Health Sciences Centre
Information provided by (Responsible Party):
Thunder Bay Regional Research Institute

Brief Summary:
This study involves imaging participants' brains using MRI. The goal is to develop a high-resolution, high-sensitivity imaging tool, hyperpolarized xenon functional brain magnetic resonance imaging, which can provide more sensitive measurement of brain function, facilitating the development of drugs for more successful treatment of Alzheimer's disease.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Other: Traditional Proton fMRI Other: Hyperpolarized Xenon-129 fMRI Drug: Hyperpolarized Xenon-129 Device: 1H-129Xe Dual-Tuned Quadrature Head Coil Early Phase 1

Detailed Description:

The described study is a pilot study in which the investigators aim to develop an enhanced sensitivity tool for assessment of neural function. Participation involves at least two study visits no longer than three hours in length each. During visit 1, informed consent and screening for eligibility will take place. During visit 2, fMRI scanning will take place in which participants will complete simple tasks. Two types of MRI scans will be performed: traditional proton fMRI and hyperpolarized xenon-129 fMRI (HP 129Xe fMRI) scans. The trade name for xenon-129 hyperpolarized with a Xemed LLC polarizer is NeuroXene.

Participants will be placed in the 3T MRI at the Thunder Bay Regional Research Institute with a Clinical MR Solutions (CMRS) Dual Brain Coil that fits over their head like a helmet. Several inhalation procedures will be performed by participants when breathing NeuroXene from a tube in the scanner. Preparation and administration of NeuroXene and the CMRS Dual Brain Coil will be carried out according to the SOP's developed by the TBRRI and Xemed LLC.

MRI scanning will be performed with a MR Tech and Registered Respiratory Therapist present. Dispensing of 129Xe will be monitored using a gas dispensing form and a drug accountability log. This study will have a monitor assigned to it from the TBRRI that is not involved in this clinical trial. This is to ensure participant safety and adherence to the protocol.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Hyperpolarized Xenon-129 Functional Magnetic Resonance Imaging of Healthy Volunteers and Participants With Alzheimer's Disease
Study Start Date : June 2016
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Xenon

Arm Intervention/treatment
Healthy Volunteers
Healthy volunteers will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
Other: Traditional Proton fMRI
Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).

Other: Hyperpolarized Xenon-129 fMRI
HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
Other Name: HP 129Xe fMRI

Drug: Hyperpolarized Xenon-129
Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
Other Name: NeuroXene

Device: 1H-129Xe Dual-Tuned Quadrature Head Coil
A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.

Alzheimer's Disease Participants
Alzheimer's disease participants will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
Other: Traditional Proton fMRI
Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).

Other: Hyperpolarized Xenon-129 fMRI
HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
Other Name: HP 129Xe fMRI

Drug: Hyperpolarized Xenon-129
Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
Other Name: NeuroXene

Device: 1H-129Xe Dual-Tuned Quadrature Head Coil
A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.




Primary Outcome Measures :
  1. Signal-to-Noise Ratio (SNR) [ Time Frame: Three years ]
    All scans will be optimized for the highest SNR possible; No aggregation of data


Secondary Outcome Measures :
  1. P-Value [ Time Frame: Three years ]
    To be calculated from a students paired t-test for signal change between healthy participant scans and participants with Alzheimer disease



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

A participant is eligible for inclusion in the study if the individual meets all of the following criteria:

  1. Self-reported proficiency in English language.
  2. Equal to or more than 8 years of education.
  3. Normal or corrected to normal vision.
  4. Able to provide informed consent.
  5. Able to hold their breath for 20 seconds.

Normal cognition for healthy participant group inclusion criteria:

  1. Preserved independence in functional abilities.
  2. MoCA score no less than 26.
  3. Males and non-lactating females of 18 to 85 years of age.

Alzheimer's disease group inclusion criteria:

  1. Participants meet National Institute on Aging-Alzheimer's Association for probable or possible Alzheimer's Disease dementia.
  2. MoCA score no less than 16.
  3. Males and non-lactating females of 60 to 85 years of age.
  4. Have a family member, close friend, or LAR that can be present for the informed consent process and study visits.

Exclusion Criteria:

A participant is ineligible for the study if the individual meets any of the following criteria:

  1. Serious underlying medical condition, other, then the condition being investigated, which may affect cognitive function of the participant (in the opinion of the investigator): substance abuse, psychotic or depressive disorder, advanced or poorly controlled cardiac, pulmonary, hepatic, renal, neurological disorders in which the patient has significant speech, visual, motor or cognitive deficit, seizure disorders, endocrine or infectious disease or active malignancy.
  2. MRI incompatibility as determined by MR Technologist during MRI screening.
  3. Self-identifies as claustrophobic.
  4. Female exclusion only: Are or may be pregnant; Planning on becoming pregnant.
  5. Is a student currently enrolled in a course at Lakehead University where the Principal Investigator (PI) is the instructor.
  6. Is a student currently enrolled in a degree program at Lakehead University where the PI is their direct thesis supervisor.
  7. Is currently an employee of the PI at the Thunder Bay Regional Research Institute (TBRRI) and/or Lakehead University.

Normal cognition group exclusion criteria:

1. History of diagnosed neurological disease or injury.

Alzheimer's disease group exclusion criteria:

  1. Existing diagnosis of dementia of etiology other than Alzheimer's disease.
  2. Acute Delirium on the day of scanning (CAM tool assessment)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02638519


Contacts
Layout table for location contacts
Contact: Mitchell Albert, Ph.D. 807-684-7270 albertmi@tbh.net
Contact: Jennifer Plata, HBSc 807-684-7270 plataj@tbh.net

Locations
Layout table for location information
Canada, Ontario
Thunder Bay Regional Health Sciences Centre Recruiting
Thunder Bay, Ontario, Canada, P7B 6V4
Contact: Mitchell S Albert, PhD    807-684-7270    albertmi@tbh.net   
Contact: Francis Hane, PhD    807-684-6958    hanef@tbh.net   
Principal Investigator: Mitchell S Albert, PhD         
Sub-Investigator: Jane Lawrence-Dewar, PhD         
Sub-Investigator: Francis Hane, PhD         
Sub-Investigator: Ayman Hassan, MD         
Sub-Investigator: Alla Reznik, PhD         
Sub-Investigator: Karl Granberg, MD         
Sub-Investigator: Anton Kolobov, MD         
Sponsors and Collaborators
Thunder Bay Regional Research Institute
Lakehead University
Thunder Bay Regional Health Sciences Centre
Publications:
Layout table for additonal information
Responsible Party: Thunder Bay Regional Research Institute
ClinicalTrials.gov Identifier: NCT02638519    
Other Study ID Numbers: RP-307-08312015
First Posted: December 23, 2015    Key Record Dates
Last Update Posted: August 9, 2018
Last Verified: October 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Xenon
Anesthetics, Inhalation
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs